Kymriah

Tisagenlecleucel, the active ingredient in Kymriah, is a CAR T-cell therapy presented as a cell suspension for intravenous infusion for intravenous use. It treats B‑cell precursor acute lymphoblastic leukemia in patients up to 25 years and relapsed or refractory large B‑cell lymphoma in adults and is authorized in the EU market.

GNH USA supplies Kymriah as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kymriah is a CAR T‑cell therapy that targets CD19‑positive B‑cell malignancies. - B‑cell precursor acute lymphoblastic leukemia (ALL) in patients up to 25 years: provides targeted cellular therapy aiming for remission. - Relapsed or refractory large B‑cell lymphoma in adults: delivers CD19‑directed cytotoxic activity to reduce tumor burden. - CD19‑positive B‑cell malignancies (clinical trials): being studied for additional therapeutic benefit.

Kymriah may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Cytokine release syndrome: fever, hypotension, and hypoxia. - Neurologic toxicity (ICANS): confusion, aphasia, or seizures. - Fatigue and malaise. - Nausea and vomiting. - Headache. - Low blood counts (neutropenia, thrombocytopenia).

Serious or Rare Side Effects: - Tumor lysis syndrome. - Severe infections, including opportunistic pathogens. - Prolonged cytopenias lasting weeks to months. - B‑cell aplasia leading to hypogammaglobulinemia. - Secondary malignancies. - Life‑threatening neurotoxicity.

Before initiating therapy, clinicians should evaluate patient eligibility and monitor for known risks. - Patient selection: confirm CD19 expression and meet age/clinical criteria. - Baseline assessment: obtain complete blood count, organ function, and disease status. - Monitoring: observe closely for cytokine release syndrome and neurotoxicity during and after infusion. - Infection risk: implement prophylactic antimicrobial measures as indicated. - Vaccination: avoid live vaccines during treatment and for a defined period afterward. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tisagenlecleucel may interact with other therapies that affect immune function.

Major Interactions (Avoid): - Concurrent use of other CAR T‑cell products: overlapping toxicities. - Live viral vaccines: can exacerbate immune response. - Immunosuppressive chemotherapy within 2 weeks: may impair efficacy.

Moderate Interactions (Monitor Closely): - Corticosteroids: may reduce CAR T‑cell expansion, monitor disease response. - Antibiotics for infection prophylaxis: adjust dosing as needed.